Arbutus Biopharma has filed a patent for compositions and methods used in administering nucleic acid based therapies, specifically liposomes and lipoplexes. The patent claim describes a preparation containing compounds with a specific structure defined by formula (I) or a pharmaceutically acceptable salt. GlobalData’s report on Arbutus Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arbutus Biopharma, peptide pharmacophores was a key innovation area identified from patents. Arbutus Biopharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
"nucleic acid based therapy compositions and methods"
A recently filed patent (Publication Number: US20230174459A1) describes a preparation that includes one or more compounds with a specific chemical structure defined by formula (I) or a pharmaceutically acceptable salt thereof. The patent also includes various claims related to specific compounds and their properties.
The patent claims include the identification of specific compounds of formula (X) and (XV), along with their variations. For example, claim 326 states that the compound of claim 325 (formula XV) has both L1 and L2 as a bond, while claim 327 specifies that L1 and L2 are both C(O). Claim 328 mentions that each R1 and R2 are independently alkyl, and claim 329 further specifies that they are independently C6-C28 alkyl. Claim 330 states that both R1 and R2 are straight chain alkyl with the same length, and claim 331 specifies that they are C14 alkyl.
The patent also includes claims related to compounds with alkenyl groups (claim 335) and compounds with a specific structure of two double bond moieties (claim 337). Claim 338 mentions that X is -C(O)NH-, resulting in a compound of formula (XV').
Furthermore, the patent claims describe the use of these compounds in lipid nanoparticles. Claim 350 states that a lipid nanoparticle comprises a compound of claim 325, and claim 351 adds that the lipid nanoparticle can also include a therapeutic agent. Finally, claim 352 describes a method for treating a patient with a disease or disorder by administering a therapeutically effective amount of the lipid nanoparticle of claim 351 to the patient.
In summary, the filed patent describes a preparation comprising compounds with specific chemical structures and their variations. The patent also includes claims related to the use of these compounds in lipid nanoparticles and their potential therapeutic applications.
To know more about GlobalData’s detailed insights on Arbutus Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
